TY - JOUR
T1 - Difficulty in differential diagnosis for renal cancer with microscopic papillary architecture
T2 - Overlapped pathological features among papillary renal cell carcinoma (RCC), mutinous tubular and spindle cell carcinoma, and unclassified RCC. Lessons from a Japanese multicenter study
AU - Ito, Keiichi
AU - Mikami, Shuji
AU - Kuroda, Naoto
AU - Nagashima, Yoji
AU - Tatsugami, Katsunori
AU - Masumori, Naoya
AU - Kondo, Tsunenori
AU - Takagi, Toshio
AU - Nakanishi, Shotaro
AU - Eto, Masatoshi
AU - Kamba, Tomomi
AU - Tomita, Yoshihiko
AU - Matsuyama, Hideyasu
AU - Tsushima, Tomoyasu
AU - Nakazawa, Hayakazu
AU - Oya, Mototsugu
AU - Kimura, Go
AU - Shinohara, Nobuo
AU - Asano, Tomohiko
N1 - Funding Information:
This work was supported in part by grants-in-aid for scientific research (#19 K07468 to S.M., #17 K11162 to Y.N.) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.
Funding Information:
Naoya Masumori MD reports receiving research funding from Ono. Tsunenori Kondo MD reports receiving honoraria from Bayer, Novartis and Pfizer during the conduct of the study. Masatoshi Eto MD reports receiving research funding and honoraria from Novartis, Ono and Pfizer and honoraria from Bayer, Bristol-Myers Squibb during the conduct of the study. Yoshihiko Tomita MD reports receiving research funding and honoraria from Astellas, Ono and Pfizer; research founding from AstraZeneca and honoraria from Bristol-Myers Squibb and Novartis and consultancy fees from Novartis, Ono; and Taiho during the conduct of the study. Hideyasu Matsuyama MD reports receiving honoraria from Bayer, Ono and Pfizer during the conduct of the study. Hayakazu Nakazawa MD reports receiving honoraria from Bayer, Novartis and Pfizer during the conduct of the study. Mototsugu Oya MD reports receiving research funding; and honoraria from Novartis, Ono and Pfizer and honoraria from Bayer during the conduct of the study. Go Kimura MD reports receiving research funding and honoraria from Ono, Bristol-Myers Squibb and Bayer, and honoraria from Novartis and Pfizer during the conduct of the study; Nobuo Shinohara MD reports receiving honoraria from Novartis and Pfizer and is an advisor for Ono during the conduct of the study. Other authors declare that they have no conflict of interest. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional committee in each institution and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Publisher Copyright:
© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com
PY - 2021
Y1 - 2021
N2 - Objectives: In our multicenter study evaluating metastatic papillary renal cell carcinoma (PRCC), 29% of tumors diagnosed as PRCC in collaborative institutes were finally diagnosed as other RCCs under central review. In those tumors, mucinous tubular and spindle cell carcinoma (MTSCC) was the leading histology, followed by unclassified RCC (ucRCC). We focused on those patients with MTSCC or ucRCC. Methods: We reviewed the processes for the pathological diagnoses of nine tumors and reviewed their clinical features. Results: All of the MTSCCs and ucRCCs were positive for AMACR, which is frequently positive in PRCC. Mucin was demonstrated in 80% of the MTSCCs, and its presence is important for their diagnoses. One MTSCC was diagnosed as a mucin-poor variant. The presence of spindle cells with low-grade nuclei was suggestive of MTSCC, but the diagnosis of high-grade MTSCC was difficult. Four tumors were diagnosed as ucRCC by histological and immunohistochemical findings. Three of the four tumors were suspicious of ucRCC in the initial review due to atypical findings as PRCC. Sunitinib and interferon-α were effective for one MTSCC patient who survived for >5 years. Two MTSCC patients who were Memorial Sloan-Kettering Cancer Center poor risk had unfavorable prognoses. One patient with mucin-poor MTSCC had an indolent clinical course. Two of four ucRCC patients showed durable stable disease with targeted agents (TAs) and survived >3 years. Conclusion: Some MTSCC metastases progressed very slowly and poor-risk tumors progressed rapidly. Systemic therapies including TAs showed some efficacies. Some patients who have metastatic ucRCC with microscopic papillary architecture can benefit from TAs.
AB - Objectives: In our multicenter study evaluating metastatic papillary renal cell carcinoma (PRCC), 29% of tumors diagnosed as PRCC in collaborative institutes were finally diagnosed as other RCCs under central review. In those tumors, mucinous tubular and spindle cell carcinoma (MTSCC) was the leading histology, followed by unclassified RCC (ucRCC). We focused on those patients with MTSCC or ucRCC. Methods: We reviewed the processes for the pathological diagnoses of nine tumors and reviewed their clinical features. Results: All of the MTSCCs and ucRCCs were positive for AMACR, which is frequently positive in PRCC. Mucin was demonstrated in 80% of the MTSCCs, and its presence is important for their diagnoses. One MTSCC was diagnosed as a mucin-poor variant. The presence of spindle cells with low-grade nuclei was suggestive of MTSCC, but the diagnosis of high-grade MTSCC was difficult. Four tumors were diagnosed as ucRCC by histological and immunohistochemical findings. Three of the four tumors were suspicious of ucRCC in the initial review due to atypical findings as PRCC. Sunitinib and interferon-α were effective for one MTSCC patient who survived for >5 years. Two MTSCC patients who were Memorial Sloan-Kettering Cancer Center poor risk had unfavorable prognoses. One patient with mucin-poor MTSCC had an indolent clinical course. Two of four ucRCC patients showed durable stable disease with targeted agents (TAs) and survived >3 years. Conclusion: Some MTSCC metastases progressed very slowly and poor-risk tumors progressed rapidly. Systemic therapies including TAs showed some efficacies. Some patients who have metastatic ucRCC with microscopic papillary architecture can benefit from TAs.
KW - Clinical outcome
KW - Immunostainings
KW - Metastatic mucinous tubular and spindle cell carcinoma
KW - Microscopic papillary architecture
KW - Systemic therapy
KW - Unclassified renal cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85094121559&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85094121559&partnerID=8YFLogxK
U2 - 10.1093/JJCO/HYAA114
DO - 10.1093/JJCO/HYAA114
M3 - Article
C2 - 33089867
AN - SCOPUS:85094121559
SN - 0368-2811
VL - 50
SP - 1313
EP - 1320
JO - Japanese journal of clinical oncology
JF - Japanese journal of clinical oncology
IS - 11
ER -